# ICOTYDE

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/icotyde
Canonical HTML page: https://getyourbrief.com/entity/icotyde

## Recent coverage (2 stories, network-wide)

### PTGX's 2 Shot-on-Goal Strategy: ICOTYDE Approved, Rusfertide Priority Review, $620M Cash
2026-06-14 01:25:38 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2

Protagonist Therapeutics has transitioned from binary clinical risk to execution risk, with ICOTYDE's FDA approval and rusfertide's Priority Review. Backed by $620 million in cash, the company's validated peptide platform and royalty-based revenue model offer a compelling biotech investment thesis.
Full story: https://getbiobrief.com/story/ptgx-2-shots-on-goal-icotyde-approved-rusfertide-priority-review

### How Protagonist’s $620M Cash Runway Through 2028 Supports 2 Peptide Drug Launches
2026-06-14 01:25:03 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2

Protagonist Therapeutics' shift to a royalty-driven, capital-light model ensures sustained funding for two near-term peptide drug launches. With over $620 million in cash, the company is poised to deliver new treatment options while minimizing financial risk.
Full story: https://gethealthbrief.com/story/protagonist-therapeutics-620m-cash-runway-2-drug-launches-health

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.